You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

 

Online download statistics by month:

Online download statistics by month: May 2020 to June 2025

AbstractFullPdf
May 2020179179106
Jun 202017517587
Jul 2020656556
Aug 2020565431
Sep 202010010066
Oct 2020686848
Nov 2020919183
Dec 2020797951
Jan 2021828242
Feb 2021959559
Mar 2021959571
Apr 202110110165
May 2021717143
Jun 2021939361
Jul 202110210273
Aug 2021909073
Sep 2021808061
Oct 202110810899
Nov 2021919084
Dec 2021122124100
Jan 202212013576
Feb 2022939356
Mar 202216317995
Apr 202211311654
May 202210511685
Jun 202210111069
Jul 202211411669
Aug 20229710071
Sep 202210210656
Oct 202213114586
Nov 202211312090
Dec 2022858565
Jan 2023737336
Feb 202314414560
Mar 202310911064
Apr 2023585860
May 2023747546
Jun 2023878738
Jul 2023797944
Aug 2023616243
Sep 2023666938
Oct 2023535534
Nov 2023195195112
Dec 2023929259
Jan 2024808137
Feb 2024747451
Mar 2024104106173
Apr 2024959561
May 2024939343
Jun 202411311587
Jul 202410811150
Aug 2024616251
Sep 2024464655
Oct 2024808555
Nov 20249310075
Dec 2024798251
Jan 2025737349
Feb 2025969678
Mar 2025838561
Apr 202513113349
May 2025929452
Jun 2025515220
Total592360463963